Enliven Therapeutics (ELVN) Other Non Operating Income (2019 - 2025)
Enliven Therapeutics (ELVN) reported Other Non Operating Income of $49000.0 for Q4 2025, up 131.21% on a YoY basis from $21192.8 in Q4 2024, and up 2550.0% sequentially from -$2000.0 in Q2 2025.
Enliven Therapeutics (ELVN) Other Non Operating Income (2019 - 2025) Analysis & Trends
Enliven Therapeutics (ELVN) has 7 years of Other Non Operating Income data on file, last reported at $49000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income rose 131.21% year-over-year to $49000.0; the trailing twelve-month figure through Mar 2026 stood at $47000.0 (up 122.93% YoY), and the FY2024 full-year result was -$159000.0, changed N/A from the prior year.
- Other Non Operating Income advanced to $49000.0 in Q4 2025, from -$2000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $49000.0 in Q4 2025 to a low of -$157000.0 in Q4 2024.
- A 5-year average of -$30571.4 and a median of -$28000.0 in 2021 frame the typical range for Other Non Operating Income.
- Peak annual rise in Other Non Operating Income reached 131.21% in 2025, while the deepest fall reached 4600.0% in 2025.
- Tracing ELVN's Other Non Operating Income over 5 years: stood at -$57000.0 in 2021, then jumped by 33.33% to -$38000.0 in 2022, then jumped by 134.21% to $13000.0 in 2023, then tumbled by 1307.69% to -$157000.0 in 2024, then soared by 131.21% to $49000.0 in 2025.
- Business Quant data shows ELVN's Other Non Operating Income at $49000.0 in Q4 2025, -$2000.0 in Q2 2025, and -$47000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49,000.00 |
| Jun 30, 2025 | -2,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -157,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Sep 30, 2023 | -13,000.00 |
| Jun 30, 2022 | -38,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Dec 31, 2021 | -57,000.00 |
| Sep 30, 2021 | -18,000.00 |
| Jun 30, 2021 | -40,000.00 |
| Mar 31, 2021 | -60,000.00 |
| Dec 31, 2020 | -83,000.00 |
| Sep 30, 2020 | -55,000.00 |
| Jun 30, 2020 | -12,000.00 |
| Mar 31, 2020 | 5,000.00 |
| Dec 31, 2019 | 69,000.00 |
| Sep 30, 2019 | 6,000.00 |